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Abstract
Over the past decade, the role of surgery in stage IV colorectal cancer (CRC) has evolved,
yet the optimal surgical management of the primary tumor in patients with metastatic
CRC that is not amenable to curative resection is unknown. A high rate of surgical
resection  of  the  primary  tumor  has  been  reported  in  patients  with  unresectable
metastatic disease. Resection of the primary tumor in patients with metastatic CRC is
often performed to deal with presenting primary tumor symptoms and or to prevent
future primary tumor complications. Nevertheless, with access to novel agents and their
efficacy in the primary tumor as well as lack of major complications related to an intact
primary  tumor,  surgery  is  less  commonly  performed  today.  Although  the  data
regarding survival  advantages  of  resection of  the  primary tumor are  inconsistent,
overall the evidence suggests potential survival benefit of removal of the primary tumor
in patients with both symptomatic and asymptomatic primary tumors even with access
to  more  effective  combination  chemotherapy.  However,  the  published  literature
favoring surgery mostly comprises retrospective observational studies. Consequently,
the survival benefit related to surgery has been attributed to selection bias, and in the
absence of randomized controlled trial no definite conclusion can be drawn. Current‐
ly, two randomized controlled trials are enrolling patients to answer this important
question in the management of metastatic CRC.
Keywords: Primary tumor resection, stage IV colorectal cancer, palliative surgery,
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1. Introduction
The role of surgery in stage IV colorectal cancer (CRC) has evolved over the past two decades.
Surgery has become an important treatment component in the management of patients with
metastatic CRC [1–3]. Between 30 and 38% of patients diagnosed with stage IV CRC will undergo
one or more major surgical procedures [4]. The known 5-year survival rate after liver and lung
metastasectomy has been reported to be 25 to 51% and 30 to 73%, respectively [5]. Although
administration of systemic therapy in patients with stage IV CRC may convert unresectable into
resectable disease, in a majority of patients, the metastatic disease is not resectable. For most
patients with advanced CRC, systemic chemotherapy is the primary treatment and the focus of
management is on how best to palliate the symptoms and to prolong survival (Figure 1) [1].
With the availability of several novel agents and increasing use of liver-directed therapies, the
median overall survival of patients with metastatic CRC has improved from 6 months with best
supportive care alone to 30 months with the use of combination therapy [6].
Figure 1. Framework of management of patients with stage IV CRC. Most patients are primarily treated with chemo‐
therapy, nevertheless, a selected group of patients can be cured with primary tumor resection and metastasectomy.
Currently, the role of resection of primary tumor in patients with unresectable metastatic disease is not well defined
(Adapted with permission from Ahmed et al. [1]).
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Even though enormous progress has been made in the treatment of patients with CRC within
the past three decades, the optimal management of patients with metastatic disease not
amenable to curative therapy who present without severe primary tumor-related symptoms
has remained controversial. Resection of the primary tumor in patients with metastatic CRC
is often performed to deal with presenting primary tumor symptoms and/or to prevent future
primary tumor complications. Potential advantages of resection of the primary tumor in stage
IV CRC are prevention of obstruction and major bleeding, better pain control, and potential
reduction in serious adverse effects related to novel targeted therapy such as bleeding and
perforation. Conversely, the newer generation chemotherapy in combination with targeted
therapy has been associated with response rate of 40–60% [7]. Complications following
resection of the primary tumor in patients with advanced CRC can delay or prevent initiation
of systemic therapy and thereby precludes benefit associated with it. There is no evidence that
response rates of the primary tumor are inferior to that of the metastases.
Recent data suggest that resection of the primary tumor in patients with stage IV CRC has been
associated with a lower mortality risk [8]. Nevertheless, most studies failed to adjust for
important prognostic variables such as performance status. In this chapter we will review the
evidence regarding the benefit of resection of the primary tumor, limitations of the current
evidence and future directions.
2. Argument for surgery
Resection of the primary tumor by lowering the tumor burden may maximize the benefit of
chemotherapy and increase the potential for surgery with a curative intent. Evidence from
other solid tumors such as renal cell cancer supports resection of the primary tumor in patients
with metastatic disease. Two well-designed randomized trials demonstrated significant
survival benefit for patients with metastatic renal cancer undergoing nephrectomy prior to
systemic therapy. For example, Flanigan et al. reported median overall survival times of 11.1
compared with 8.1 months and Mickisch et al. of 17 versus 7 months in favor of nephrectomy
[9, 10]. Surgical resection of the primary tumor in metastatic CRC may prevent complications
caused by the primary tumor that may subsequently require emergency interventions which
are associated with increased peri-operative mortality and unfavorable long-term outcome.
Stillwell and others have shown that patients who were initially treated with chemotherapy
were 7.3 times more likely to have a complication from the primary tumor and, when operated
for such complications, were more likely to have a poor postoperative outcome [11–13].
3. Argument against surgery
Over the past decade, several highly active systemic agents, both cytotoxic and biologic, have
become available for the treatment of patients with metastatic CRC. As a result, the median
survival of patients with stage IV CRC has increased from 9 to 12 months with fluorouracil
alone to up to 24 to 30 months with sequential modern cytotoxic and biologic treatments [1].
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There remains concern of primary tumor–related complications during systemic therapy
particularly with a risk of perforation when combining anti-VEGF (vascular endothelial
growth factor) therapy to cytotoxic agents [14]. Recent studies, however, have demonstrated
that combination chemotherapy and biological agents can be safely administered in patients
with metastatic CRC with an in situ primary tumor [12, 15, 16]. A recent phase II trial utilizing
bevacizumab containing regimen reported 14% primary tumor complications rate [17]. The
author concluded that the survival is not compromised by leaving the primary colon tumor
intact.
4. Evidence from the literature
The evidence regarding benefit of primary tumor resection, in patients with stage IV CRC and
unresectable metastatic lesions is not conclusive. The published literature about survival
advantages of removal of primary tumor is inconsistent; while some suggest benefit of surgery
[8], others have failed to demonstrate survival benefit of non-curative resection of the primary
tumor [18, 19].
Cirrochi and others performed a systematic review of seven non-randomized eligible studies
involving 1086 patients. Of 1086 patients, 722 (66.4%) underwent primary tumor resection, and
364 (33.6%) were managed with chemotherapy alone [18]. The author concluded that resection
of the primary tumor in asymptomatic patients with metastatic CRC was not associated with
a consistent improvement in overall survival. Furthermore, primary tumor resection did not
significantly reduce the risk of complications from the primary tumor. Another review by
Scheer and others that specifically focused on complication rates of the primary tumor did not
support surgery. Based upon the data on 850 patients from 7 papers published from 1999 to
2006 when first-line chemotherapy was administered in patients with unresectable stage IV
CRC, obstruction and intestinal hemorrhage were observed in 13.9% and 3% of the patients,
respectively. On the other hand, when upfront surgery of the primary tumor was performed,
complications rates were 18.8–47%. Of note, two of 7 studies in this review did not have a
surgical intervention group [19].
Our research group conducted a systematic review and meta-analysis of the current literature
[8]. Of total of 3379 reports, 15 retrospective observational studies were selected with patients
population of 12456 (Table 1) [12, 13, 20–31]. Six studies were exclusively done in minimally
symptomatic patients and 10 studies met the criteria of using new generation anti-cancer
therapy. All included studies were retrospective observational studies. No study met the
criteria for good quality study using ‘validity scoring for observational study’ for any outcome
of interest. Overall, 26% patients had rectal tumor, 21.9% in the resection group compared with
31% in the control. For the primary outcome “overall survival” 9 of 15 studies were of low
quality and remaining 6 were fair quality. Among 12,456 patients, 8620 (69%) underwent
surgery with a median overall survival of the 15.2 months (range: 10–30.7) compared with 11.4
months (range: 3–22) of the non-resection group. Quantitative meta-analysis utilizing the data
of all 15 studies revealed that the primary tumor resection was associated with a significant
improvement in survival compared with no surgery with a hazard ratio (HR) of 0.69 (95%
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confidence interval [CI]: 0.61–0.79). Nine studies reported surgical mortality rate. Mean 30 days
post-operative mortality rate in the intervention group was 4.9% (95% CI: 0–9.7%). Only seven
studies reported non-fatal surgical complications including anastomic leak, surgical wound
infection and other complications. The mean surgical morbidity rate was 25.9% (95% CI: 20.1–
31.6). Mean primary tumor complications rate & non-surgical procedures rate in the control
group were 29.7% (95% CI: 18.5–41.0) and 27.6% (95 CI: 15.4–39.9), respectively. No study
provided quality of life data. In a sub-group analysis involving studies during the period of
modern chemotherapy, the median overall survival of group with surgery was 18.7 months
(range: 11–30.7) compared with 12.85 months (range: 5.8–22) in the control group. The HR for
survival of the subgroup treated with irinotecan and or oxaliplatin based chemotherapy was
in 0.68 (95% CI: 0.56-0.83) favoring the surgical intervention compared with HR of 0.73 (95%
CI: 0.59–0.90) of the group treated with older regimen. Likewise, in a separate sub-group
analysis of studies restricted to minimally symptomatic tumor from the primary tumor, the
median overall survival of group with surgery was 18.5 months (range: 14.5–23) versus 13.15
months (range: 5.8–22) in the control group. The HR for survival of minimal symptomatic
patients was 0.67 (95% CI: 0.48–0.94) favoring the intervention group compared with HR of
0.75 (95% CI: 0.67–0.84) of symptomatic patients. A substantial low quality studies, publica‐
tions bias and selected reporting were the major limitations of the review. Consequently, the
survival benefit related to surgery has been attributed to selection bias and selection of younger
and healthier patients with good performance status.
To address some of the limitations reported in the literature our research group conducted a
cohort study to evaluate survival benefit of surgery (Table 2) [32]. The study population was
comprised of adult patients with histologically documented adenocarcinoma of colon and
rectum, intact primary tumor and evidence of metastases, diagnosed between the period of
1992 and 2005, in the Canadian province of Saskatchewan. In this large population based cohort
study individual medical records were reviewed to retrieve information about important
prognostic variables including performance status. A total 1378 eligible patients with median
age of 70 years were identified. Five hundred and forty four (39.5%) patients were sympto‐
matic. Nine hundred and forty four (68.5%) patients underwent resection of the primary
tumor. Of 1378 patients, 29.5% had rectal or recto-sigmoid tumor (rectal, 20.1%, recto-sigmoid,
9.4%). Among 1378 patients, 42.3% received chemotherapy and 45.1% received 2nd generation
(irinotecan and/or oxaliplatin based) therapy. Patients who underwent primary tumor
resection and received chemotherapy had median overall survival of 18.3 months (95%CI:
16.6–20) compared with 8.4 months (95% CI: 7.1–9.7) if they were treated with chemotherapy
alone (p<0.0001). In a subgroup of patients who were treated with second generation chemo‐
therapy, median survival of patients who underwent surgical resection of primary tumor was
24.6 months (95% CI: 20.2–29.0) versus 11.0 months (95% CI: 7.8–14.3) if they did not have
surgery. Due to imbalance between the two groups with respect to important prognostic
variables such as chemotherapy, metastasectomy, and performance status a Cox proportional
multivariate analysis was performed. The analysis revealed that resection of the primary tumor
was independently correlated with better survival after adjustment for important clinical and
pathological variables. For example, use of chemotherapy (HR 0.47, 95% CI: 0.41–0.54),
primary tumor resection (HR 0.49, 95% CI: 0.41–0.58), second line chemotherapy (0.47, 95% CI:
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0.45-0.64), and metastasectomy (HR 0.54, 95% CI: 0.45-0.64) were correlated with superior
survival whereas older age, poor performance status, low albumin, elevated bilirubin, elevated
alkaline phosphatase, anemia, leukocytosis, colonic primary, and grade 3 tumor were corre‐
lated with inferior survival. The tests for interactions between the surgical resection of primary
tumor and second line therapy or more than 2 metastatic sites, were significant suggesting
greater benefit of surgery in patients who received further line of therapies or who had limited
metastases. Since patients who undergo metastasectomy have potential to achieve long term
survival, a secondary analysis, after excluding patients who underwent metastasectomy was
performed. In the secondary analysis, surgical resection of primary tumor significantly
correlated with better survival (adjusted HR of 0.43; 95% CI: 0.41–0.52).
Study and year
of publication
Study design Study
duration
N Patients Co-interventions Outcomes
Aslam et al. 2010 [26] Retrospective multi-
centers
observational study
1998–2007 T: 647 I: 366
C: 281
Minimally
symptomatic
Chemotherapy I:
63%, C: 36%
Median OS 14.5 (I) vs. 5.8
(C) months (p<0.05);
post-operative mortality (I) 7%
Benoist et al. 2005 [12] Retrospective single
institutional case–
control study
1997–2002 T: 59 I: 32 C: 27 Asymptomatic or
minimally
symptomatic
Chemotherapy I: 94%,
C: 100%; metastasectomy I:
16%, C: 22%
Median OS 22 (I) vs. 23
(C) months (p=NS);
post-operative mortality (I) 0%
Chan et al. 2010 [27] Retrospective
population
based study
2000–2002 T: 411 I: 286 C:
125
Symptomatic &
asymptomatic
Chemotherapy I: 61%,
C: 58%; metastesectomy I:
10%, C: 0%
Median OS 14 (1) vs. 6 (C) months
(p=<0.05)
Evans et al. 2009 [28] Retrospective single
institutional
observational study
1999–2006 T: 97 I: 45 C: 52 Symptomatic &
asymptomatic
Chemotherapy I: NP, C: 42% Median OS 11 (I) vs. 7 (C)
months (p=NS), post-operative
mortality (I) 16%
Galizia G et al. 2008 [24] Retrospective single
institutional
observational study
1995–2005 T: 65 I: 42 C: 23 Asymptomatic or
minimally
symptomatic
Chemotherapy I: 100%,
C: 100%; metastasectomy I:
12%, C: 4%
Median OS 15.2 (I) vs. 12.3
(C) months (p=0.003);
post-operative mortality (I) 0%
Karoui M et al. 2011 [21]Retrospective multi-
centers
observational study
1998–2007 T: 208 I: 123 C:
85
Symptomatic &
asymptomatic
Chemotherapy I: 100%,
C: 99%; metastasectomy I:
23%, C: 29%
Median OS 30.7 (I) vs. 21.9 (C)
months (p=0.004)
Konyalian et al. 2007
[29]
Retrospective single
institutional cohort
study
1991–2002 T: 109 I: 62 C: 47 Symptomatic &
asymptomatic
Chemotherapy I: 71%,C: 60%; Median OS 12.5 (I) vs. 4.6 (C)
months (p<0.05); post-operative
mortality (I) 5%
Michel et al. 2004 [30] Retrospective single
institutional
observational study
1996–1999 T: 54 I: 31 C: 23 Asymptomatic or
minimally
symptomatic
Chemotherapy I: 97%,C:
100%; metastesectomy I: NP,
C: 9%
Median OS 21 (I) vs. 14 (C)
months (p=NS); post-operative
mortality (I) 0%
Ruo et al. 2003 [13] Single institutional
retrospective
observational study
1996–1999 T: 230 I: 127 C:
130
Asymptomatic or
minimally
symptomatic
Chemotherapy I: NP, C: 83% Median OS 16 (I) vs. 9 (C) months
(p=<0.05); post-operative
mortality (I) 2%
Scoggins et al.1999 [22] Single institutional
retrospective
observational study
1985–1997 T:89 I:66 C:23 Symptomatic &
asymptomatic
NP Median OS 14.5 (I) vs. 16.6 (C)
months (p=NS)
Seo et al. 2010 [31] Single institutional
retrospective
observational study
2001–2008 T:277 I:144 C:83 Asymptomatic or
minimally
symptomatic
Chemotherapy I: 100%, C:
100%;
Median OS 22 (I) vs. 14 (C)
months (p=NS); post-operative
mortality (I) 0%
Tebutt et al. 2003 [23] Single institutional
retrospective
observational study
1990–2000 T:362 I:208 C:82 Symptomatic &
asymptomatic
Chemotherapy I: 100%, C:
100%; metastasectomy I: 2%,
C: 1%
Median OS 14 (I) vs. 8.2 (C)
months (p=NS)
Temple et al. 2004 [25] Population based study
using SEERS &
Medicare data
1991–1999 T:9011 I:6464 C:
2542
65 years or older
symptomatic &
asymptomatic
Chemotherapy I: 47%, C:
31%; metastasectomy I: 5.2%,
C: 1.3%
Median OS 10 (I) vs. 3 (C) months
(p<0.05); post-operative mortality
(I) 9%
Venderbosch et al. 2011
(CAIRO) [20]
Retrospective multi-
centers cohort of a RCT
2003–2004
(recruited
period)
T:399 I:258 C:
141
Symptomatic &
asymptomatic
100% chemotherapy in both
groups
Median OS 16.7 (I) vs. 11.4 (C)
months
Venderbosch et al. 2011
(CAIRO 2) [20]
Retrospective multi-
centers cohort of a RCT
2005–2006
(recruited
period)
T:488 I:289 C:
159
Symptomatic &
asymptomatic
100% chemotherapy in both
groups
Median OS 20.7 (I) vs. 13.4 (C)
months
C=control group; I=intervention group; N=number; NP=not provided; NS=not significant; OS=overall survival;
RCT=randomized controlled trial; T=total.
Table 1. Summary of studies that evaluated benefit of resection of primary tumor and were included in a systematic
review and meta-analysis.
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Study & year
of publication
Study design Study
duration
N Patients Co-interventions Outcomes*
Ahmed et al.
2013 [32]
Retrospective
Population
based cohort study
1992–2005 T: 1378 I:
944 C: 434
Symptomatic &
asymptomatic
Chemotherapy I: 50%, C: 20%
metastasectomy I: 19.4%,
C: 3.5%
Median OS 18.3 (I) vs. 8.4 (C)
months (p<0.001); post-operative
mortality (I) 6.6%
Ahmed et al.
2015 [33]
Retrospective
Population
based cohort study
1992–2005 T: 834 I: 521
C: 313
Asymptomatic or
minimally
symptomatic
Chemotherapy I: 53%, C:
28%; metastasectomy I:
20.5%, C: 2.9%
Median OS 19.7 (I) vs. 8.4 (C)
months (p<0.001); post-operative
mortality (I) 4.8%
Ahmed et al.
2015–2016 [34]
Retrospective
Population based
cohort study
2006–2010 T:569 I:313
C:256
Symptomatic &
asymptomatic
Chemotherapy I: 64%, C: 50%;
metastasectomy I: 26%, C: 3%
Median OS 27 (I) vs. 14 (C)
months(p<0.001); post-operative
mortality (I) 5%
C=control group; I=intervention group; N=number; OS= overall survival; T=total.
Table 2. Summary of three population based cohort studies that used individual patients’ data and evaluated survival
benefit of surgery of primary tumor by controlling the important prognostic variables in stage IV CRC
Our study suggests that resection of the primary tumor in patients with stage IV CRC improves
survival, independent of age, performance status, co-morbid illness and chemotherapy.
Nevertheless, the study was inclusive of symptomatic patients who tend to get benefit from
palliative resection of the primary tumor, we therefore conducted a sub-group analysis
involving a cohort of patients with asymptomatic or minimally symptomatic primary tumor
to confirm survival benefit of surgery (Table 2) [33]. A total of 834 patients with median age
of 70 years were identified. Among them, 521 (63%) patients underwent surgery and 43.3%
received chemotherapy. Patients who underwent surgery had median overall survival of 19.7
months (95% CI: 16.9–22.6) compared with 8.4 months (95% CI: 6.9–10.0) if they did not have
surgery (p<0.0001). The study once more confirmed the survival benefit of surgery after
adjustment of other important prognostic variables in a multivariate analysis. Among various
prognostic variables, 5FU-based chemotherapy (HR 0.43; 95% CI: 0.36–0.53), surgery of
primary tumor (HR 0.47; 0.39–0.57), metastasectomy (HR 0.48; 0.38–0.62), and 2nd line chemo‐
therapy (HR 0.72; 0.58–0.92) were correlated with superior survival. Test for interaction
between ≥1 metastatic sites and surgery was significant suggesting a larger benefit of surgery
in patients with stage IVA disease.
4.1. Benefit of surgery in patients treated with combination chemotherapy and biologics
Our data revealed the potential benefit of resection of the primary tumor regardless of
underlying symptoms and that patients with asymptomatic or minimally symptomatic
primary tumor who underwent surgery had similar survival benefit with overall 53% reduc‐
tion in mortality after adjustment for older age, comorbid illness, poor performance status,
disease burden, chemotherapy, and metastasectomy. Of note, a larger benefit of surgery was
noted in patients with stage IVA disease. However, only about 43% of patients were treated
with systemic therapy. Among the treated patients about 45% received irinotecan- or oxali‐
platin-based (FOLFIRI or FOLFOX) chemotherapy. Moreover, less than 5% received a
biological agent. It is not known if similar benefit can be achieved with the use of more effective
systemic therapy. Our research group undertook a study to validate our findings in a cohort
of patients with stage IV CRC who were diagnosed during the period of modern systemic
therapy. A cohort of 569 patients with stage 4 CRC diagnosed during 2006–2010 in the province
of Saskatchewan was evaluated (Table 2) [34]. Their median age was 69 years (59–95), 57.3%
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Variables  HR (95% confidence interval)
Use of any chemotherapy 
 Yes 0.33 (0.26–0.43)
 No 1
Metastasectomy 
 Yes 0.43 (0.31–0.58)
 No 1
Surgical resection of primary tumor 
 Yes 0.44 (0.35–0.56)
 No 1
Second-line treatment 
 Yes 0.50 (0.35–0.70)
 No 1
Third-line treatment 
 Yes 0.58 (0.41–0.83)
 No 1
Serum alkaline phosphatase >120 U/l 
 Yes 1.50 (1.20–1.78)
 No 1
Grade III tumors 
 Yes 1.33 (1.10–1.62)
 No 1
Leukocytosis 
 Yes 1.32 (1.05–1.66)
 No 1
Stage IVb CRC 
 Yes 1.31 (1.10–1.56)
 No
ECOG performance status >1 
 Yes 1.30 (1.04–1.57)
 No 1
HR=hazard ratio; ECOG=Eastern Cooperative Oncology Group.
Table 3. Prognostic variables that correlate with survival in stage IV CRC in a multivariate analysis [34])
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received chemotherapy, 91.4% received FOLFIRI or FOLFOX and 67% received a biologic
agent. Median overall survival (OS) of patients who underwent surgical resection of primary
tumor and received chemotherapy was 27 months compared with 14 months of the non-
resection group (p<0.0001). Median OS of patients who received all active agents and had
surgery was 39 months (95% CI: 25.1–52.9). Patients with asymptomatic primary tumor who
underwent surgery and received systemic therapy had a median OS of 34 months (95% CI:
26.6–43.4) compared with median OS of 14 months (95% CI: 11.1–17.0) if they did not have
surgery (p<0.001). Median duration of hospital stay of was 9 days (interquartile range: 7–13).
Overall, 30 days mortality rate of the group who underwent surgery was 5.4%. Fifteen of 171
(8.8%) patients with symptomatic disease compared with 2 (1.4%) of 142 patients with
asymptomatic or minimally symptomatic disease died within 30 days of surgery (p=0.003).
Post-operative complications rates were not mutually exclusive and were as followed: post-
operative wound infection, 7.3%, non-wound infection, 4.8%, anastomotic leak, 2.2%, wound
dehiscence, 1.9%, bleeding, 1.6%, and pulmonary embolism, 1.8%.
On multivariate analysis, surgery of primary tumor, HR: 0.44 (95% CI: 0.35–0.56), use of
chemotherapy, HR: 0.33 (95% CI: 0.26–0.43), metastasectomy, HR: 0.43 (95% CI: 0.31–0.58),
second line therapy, HR: 0.50 (95% CI: 0.35–0.70), and third line therapy, HR: 0.58 (95% CI:
0.41–0.83) were correlated with superior survival (Table 3). After adjustment for other
prognostic variables, only the interaction between surgical resection of primary tumor and
subsequent line of therapy was significant suggesting a differential benefit of removal of
primary tumor in patients who received other lines of therapies. In a subgroup of 345 patients
with asymptomatic or relatively asymptomatic primary tumors, surgery was significantly
correlated with better survival with HR 0.32 (95% CI: 0.22–0.45).
Other studies also supports potential advantage of resection of primary tumor in patients who
are treated with modern chemotherapy regimens. A retrospective analysis of CAIRO study
that compared combination versus sequential chemotherapy demonstrated a significantly
better median OS of 16.7 months in patients who underwent resection of primary tumor
compared with 11.4 months with no surgery (HR 0.61, 95% CI:49–0.76) [20]. Likewise, a pool
analysis of four French phase 3 trials involving 850 patients indicated survival benefit of
surgery [35]. More than two third of patients were treated with FOLFIRI or FOLFOX and about
12% received bevacizumab.
Since the publication of our meta-analysis, the resection of the primary tumor has become one
of the key issues in the management of stage 4 CRC. Several recent studies have addressed
this question in patients with symptomatic or minimally symptomatic tumors [36–39]. Ishihara
and others retrospectively evaluated 1982 patients with stage 4 CRC from 1997 to 2007 [36].
Among the whole patient population, primary tumor resection significantly improved
survival (HR: 0.46, 95% CI 0.32–0.66). However, primary tumor resection did not significantly
improve survival in patients treated in the first 5 years of the study, patients aged >65 years,
female patients, patients with right-sided colon cancer, and patients without nodal involve‐
ment. Gresham et al. [37] evaluated 517 patients with stage 4 CRC. Among them, 378 (73%)
patients underwent palliative resection of their primary tumor. Palliative resection was
associated with a longer median OS (17.9 vs. 7.9 months) and more favorable adjusted HR for
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death (0.56, 95 % CI: 0.40–0.78). In a propensity score-matched analysis, prognosis was also
more favorable in the resected group (p = 0.0017). Tarantino and others used the Surveillance,
Epidemiology, and End Results (SEER) database from 1998 to 2009 and identified 37,793
patients with stage IV CRC. Of those, 23,004 (60.9%) underwent palliative primary tumor
resection. The primary cancer resection was associated with a significantly improved OS (HR:
0.40, 95% CI: 0.39–0.42) and cancer-specific survival (HR: 0.39, 95% CI: 0.38–0.40) [38]. Yun and
others assessed 416 patients with asymptomatic unresectable stage IV CRC from year 2000 to
2008 [39]. Among 416 patients, 218 (52.4%) underwent palliative resection of the primary
tumor. Their data revealed that palliative resection was not associated with a significant
increase in survival compared with non-resection. Clancy and others performed an updated
meta-analysis of 21 eligible studies involving a total of 44,226 patients [40]. Resection of the
primary tumor in patients with unresectable metastases compared with chemotherapy alone
was associated with a lower mortality risk (odd ratio [OR] 0.28; 95% CI: 0.165–0.474; P<0.001),
translating into a difference in mean survival of 6.4 months in favor of resection (95% CI: 5.025–
7.858). Patients who underwent resection of the primary tumor were more likely to have liver
metastasis only (OR 1.551; 95% CI: 1.247–1.929), were less likely to have ≥2 metastasis (OR
0.653; 95% CI: 0.508–0.839), and were less likely to have rectal cancer (OR 0.495; 95% CI: 0.390–
0.629).
5. Time trend in surgery of the primary tumor
In spite of uncertain survival benefit, a high rate of surgical resection has been reported in
patients with unresectable metastatic disease. Nevertheless, with access to novel agents and
their efficacy in the primary tumor as well as lack of major complications related to an intact
primary tumor, surgery is less commonly performed [16, 17, 41]. Hu and others performed a
retrospective cohort study using data from the National Cancer Institute's Surveillance,
Epidemiology, and End Results CRC registry involving 64,157 patients diagnosed with stage
IV colon or rectal cancer from January, 1988, through December, 2010. Of the 64,157 patients,
43,273 (67.4%) had undergone primary tumor resection [42]. The annual rate of primary tumor
resection significantly decreased from 74.5% in 1988 to 57.4% in 2010, and a significant annual
percentage change occurred between 1998–2001 and 2001–2010 (−0.41% vs −2.39%). Among
various prognostic variables age younger than 50 years, female sex, being married, higher
tumor grade, and presence of colon tumors were correlated with primary tumor resection.
6. Mechanisms of potential survival advantages of surgery
The underlying mechanism of potential survival benefit related to the removal of primary
tumor is mostly hypothetical. It is well recognized that surgical resection of primary tumor
with or without debulking of metastatic lesions, in some malignant diseases such as ovarian
and renal cell cancer, has been associated with better survival [43, 10]. Non-curative resection
of the primary tumor in patients with advanced cancer may prevent local tumor complications
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and improve disease control by simply reducing the tumor bulk. The host-tumor interaction
plays an important role in cancer progression [44]. It is plausible that the primary tumor may
secrete cytokines that promote tumor growth and reduce response to cytotoxic agents [46].
Turner and others examined the effect of primary tumor resection on systemic inflammation
and survival in patients with stage IV CRC using the neutrophil-lymphocyte ratio (NLR) as a
biomarker of systemic inflammation [46]. The reversal of an elevated NLR following the
primary tumor resection was associated with significantly improved OS (hazard ratio, 0.53).
Hence, resection of the primary tumor by affecting the tumor-host relationship may slow the
cancer progression. Furthermore, removal of primary tumor may restore the host immune
system and may improve response to systemic therapy [47].
7. Limitations of the published literature
Most studies obtained data retrospectively. Many studies failed to provide baseline prognostic
information of resection and non-resection groups while others showed significant imbalance
in baseline characteristics of the two groups and did not make adjustment for that. Only few
studies provided detail information about the use and type of chemotherapy in each group.
In addition, to our knowledge no study have adjusted for BRAF mutation which has been
reported in about 5-11% stage IV CRC and is an important prognostic marker [48]. Although
our cohort studies were good quality studies, imbalance of several known and unknown
prognostic variables between the two groups suggests bias [32–34]
8. Future directions
At least two randomized clinical trials are currently evaluating the survival benefit of removal
of primary tumor in patients with metastatic CRC [49, 50]. The SYNCHRNOUS trial is a
multicenter German study comparing resection of the primary tumor and systemic therapy to
systemic therapy alone in patients with metastatic colon cancer which is not amenable to
curative therapy [49]. The investigators estimated that resection of the primary tumor will
prolong survival from 20 to 26 months. In addition to survival, the study is evaluating short-
and long-term safety of both treatment strategies, subsequent curative procedures, and
patients' quality of life. In this trial, 694 patients (347 per group) will be enrolled to test the
hypothesis that removal of the primary tumor has been associated with superior survival.
The CAIRO trial is a multicenter Dutch trial which is evaluating benefit of resection of the
primary tumor in patients with synchronous unresectable metastatic CRC [50]. Patients with
synchronous metastatic colon cancer with asymptomatic or minimally symptomatic primary
tumor will be randomized to systemic treatment or resection of the primary tumor followed
by systemic treatment. Unlike SYNCHRONOUS, trial patients with colon or rectal cancer are
included in this study. A total of 360 patients will be enrolled to detect a difference in median
overall survival of 13 compared with 19 months.
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9. Conclusions
Although evidence suggests possible survival benefits with surgery despite the availability
of effective chemotherapeutic agents, due to a lack of prospective clinical trials, no firm con‐
clusions can be drawn with respect to whether surgical resection of the primary tumor
should be routinely offered to all patients with newly diagnosed metastatic CRC. Currently,
two randomized controlled trials are evaluating this important question in the management
of metastatic CRC. If the magnitude of survival benefits is confirmed in future randomized
clinical trials, surgical resection of the primary tumor could potentially be a more cost effec‐
tive intervention compared with novel systemic therapy in the management of stage IV
CRC.
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